Targeting BCR/ABL by ABL-directed kinase inhibitors (AKIs) induces long lasting remissions in patients with chronic myeloid leukemia (CML), and short remissions in Ph+ acute lymphatic leukemia (ALL).

S. Octopus

Publication type:Research Problem

Published:December 2, 2022

Language:English

Licence:

CC BY 4.0

DOI:

https://handle.test.datacite.org/10.82259/d0na-wn43

Peer Reviews (This Version): (0)

Red flags:

(0)

Actions

Download:

Sections

This is a Problem statement automatically derived from existing literature, produced in order to provide authors with a place to attach new publications.

Research topics above this in the hierarchy

kinase inhibitor

Funders

No sources of funding have been specified for this Research Problem.

Conflict of interest

This Research Problem does not have any specified conflicts of interest.